Xvivo Perfusion AB (0RKL) Stock Statistics & Valuation Metrics

Xvivo Perfusion AB has a market cap or net worth of kr9.30B. The enterprise value is kr8.00K.

Xvivo Perfusion AB has 31,499,470 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xvivo Perfusion AB’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 2.68%.

The current PE Ratio of Xvivo Perfusion AB is 105.1. Xvivo Perfusion AB’s PEG ratio is -2.73.

In the last 12 months, Xvivo Perfusion AB had revenue of 812.16M and earned 25.16M in profits. Earnings per share was 0.80.

In the last 12 months, operating cash flow was 236.35M and capital expenditures -131.72M, giving a free cash flow of 191.56M billion.

Xvivo Perfusion AB pays an annual dividend of kr0.285, resulting in a dividend yield of ―

Xvivo Perfusion AB upcoming earnings date is Oct 22, 2026, TBA (Confirmed).

Xvivo Perfusion AB as a current ratio of 5.77, with Debt / Equity ratio of 5.53%

In the past 12 months, Xvivo Perfusion AB has paid 13.40M in taxes.

Xvivo Perfusion AB EV to EBITDA ratio is 37.29, with an EV/FCF ratio of -37.61.

Xvivo Perfusion AB has kr304.96M in cash and marketable securities with kr121.62M in debt, giving a net cash position of kr183.35M billion.

Gross margin is 62.85%, with operating margin of 11.45%, and net profit margin of 3.10%.

The average price target for Xvivo Perfusion AB is ―, which is 11.43% higher than the current price. The consensus rating is ―